Fundraising FoxLilly Asia Ventures — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+6 more
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)
BoardBrendan Bulik-Sullivan(Director)in
Co-investorsAtlas VentureGV (Google Ventures)Broadview VenturesF-Prime CapitalNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.